Change in cell markers (CD4, CD8, CD19, and NK cell counts) and HIV-1 viral load with time
| Cell marker . | Time after start of rituximab therapy, mo . | |||
|---|---|---|---|---|
| 1 . | 3 . | 6 . | 12 . | |
| CD4, cells/mL | ||||
| Median change | 134 | 197 | 100 | 73 |
| P | .006* | .017* | .037* | .204 |
| n | 12 | 10 | 10 | 9 |
| CD8, cells/mL | ||||
| Median change | 330 | 147 | 111 | 481 |
| P | .019* | .037* | .443 | .063 |
| n | 12 | 10 | 10 | 7 |
| CD19, cells/mL | ||||
| Median change | −110 | −82 | −4 | 43 |
| P | .002* | .009* | .507 | .397 |
| n | 12 | 10 | 10 | 7 |
| NK, cells/mL | ||||
| Median change | 20 | 17 | 12 | 13 |
| P | .109 | .202 | .284 | .09 |
| n | 12 | 10 | 10 | 7 |
| Plasma HIV-1 viral load, copies/mL | ||||
| Median change | −22 166 | −41 516 | −41 516 | −164 548 |
| P | .001* | .002* | .003* | .004* |
| n | 12 | 11 | 9 | 7 |
| Cell marker . | Time after start of rituximab therapy, mo . | |||
|---|---|---|---|---|
| 1 . | 3 . | 6 . | 12 . | |
| CD4, cells/mL | ||||
| Median change | 134 | 197 | 100 | 73 |
| P | .006* | .017* | .037* | .204 |
| n | 12 | 10 | 10 | 9 |
| CD8, cells/mL | ||||
| Median change | 330 | 147 | 111 | 481 |
| P | .019* | .037* | .443 | .063 |
| n | 12 | 10 | 10 | 7 |
| CD19, cells/mL | ||||
| Median change | −110 | −82 | −4 | 43 |
| P | .002* | .009* | .507 | .397 |
| n | 12 | 10 | 10 | 7 |
| NK, cells/mL | ||||
| Median change | 20 | 17 | 12 | 13 |
| P | .109 | .202 | .284 | .09 |
| n | 12 | 10 | 10 | 7 |
| Plasma HIV-1 viral load, copies/mL | ||||
| Median change | −22 166 | −41 516 | −41 516 | −164 548 |
| P | .001* | .002* | .003* | .004* |
| n | 12 | 11 | 9 | 7 |
Median change indicates median change of value compared with value before rituximab therapy for each time point.
Significant, P < .05.